Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · IEX Real-Time Price · USD
1.730
+0.010 (0.58%)
Jun 20, 2024, 3:06 PM EDT - Market open

Virax Biolabs Group Income Statement

Millions USD. Fiscal year is Apr - Mar.
Year
2022202120202019
Revenue
0.0100.120.1
Revenue Growth (YoY)
--23.97%-
Cost of Revenue
0.0100.130.05
Gross Profit
-00-0.010.05
Selling, General & Admin
5.331.30.510.61
Research & Development
0.40.430.120.09
Operating Expenses
5.731.730.640.7
Operating Income
-5.73-1.73-0.64-0.65
Interest Expense / Income
0.020.020.030.09
Other Expense / Income
-0.29-0.04-0.02-0.03
Pretax Income
-5.46-1.71-0.65-0.71
Net Income
-5.46-1.71-0.65-0.71
Shares Outstanding (Basic)
1100
Shares Outstanding (Diluted)
1100
Shares Change
11.15%297.67%130.43%-
EPS (Basic)
-5.10-1.80-4.10-11.40
EPS (Diluted)
-5.10-1.80-4.10-11.40
Free Cash Flow
-4.36-0.81-0.59-0.74
Free Cash Flow Per Share
-4.10-0.85-2.45-7.13
Gross Margin
-15.94%--7.62%45.81%
Operating Margin
-66963.68%--520.54%-652.05%
Profit Margin
-63748.32%--525.75%-711.32%
Free Cash Flow Margin
-50907.25%--476.65%-745.54%
EBITDA
-5.44-1.69-0.62-0.62
EBITDA Margin
-63567.64%--502.62%-620.52%
EBIT
-5.44-1.69-0.62-0.62
EBIT Margin
-63567.64%--502.62%-620.52%
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).